Abstract

Sotalol 5-mg/mL Oral Suspension

Author(s): Allen Loyd V Jr

Issue: Sep/Oct 2011 - Volume 15, Number 5

Page(s): 425

Download in electronic PDF format for $75

Abstract

A formulation for preparing Sotalol 5-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2011 Pg. 425	Sotalol 5-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Mar/Apr 2006 Pg. 144	Sotalol Hydrochloride 5-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
Sep/Oct 2005 Pg. 402-406	Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations Author(s): Sidhom Madiha B, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
May/Jun 2020 Pg. 194-197	Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Jul/Aug 2016 Pg. 328-332	Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures Author(s): Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Sep/Oct 2022 Pg. 364-368	A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans Author(s): Riepl Mike
Nov/Dec 2011 Pg. 458-463	Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Author(s): Zur Eyal
May/Jun 2006 Pg. 220	Carvedilol 1.25-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2012 Pg. 160	Labetalol Hydrochloride 5-mg/mL Injection Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 148	Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2012 Pg. 420	Esmolol Hydrochloride 10-mg/mL Injection Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 504	Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet Author(s): Allen Loyd V Jr
Jan/Feb 2014 Pg. 68	Procainamide Hydrochloride 100-mg/mL Injection Author(s): Allen Loyd V Jr
Sep/Oct 2008 Pg. 455	Propafenone 1.5-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Sep/Oct 2023 Pg. 420	Nitazoxanide 20-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 1997 Pg. 183	Spironolactone 5-mg/mL with Hydrochlorothiazide 5-mg/mL Oral Liquid Author(s): Allen Loyd V Jr